Clinical trials: Retinopathy, Diabetic
Diabetic Macular Edema, Diabetic Retinopathy
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME).
- Trial name
- NCT05607810
- Testing
- ADVM-022
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Adverum Biotechnologies, Inc.
Diabetic Retinopathy
Macular Edema Incidence/Severity Reduction With Nevanac
The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
- Trial name
- NCT00939276
- Testing
- Nepafenac ophthalmic suspension, 0.1% (NEVANAC®), Nepafenac ophthalmic suspension vehicle
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Alcon Research
Vitreous Detachment, Diabetic Retinopathy
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment
The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
- Trial name
- NCT00198471
- Testing
- Vitrase
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bausch & Lomb Incorporated
Proliferative Diabetic Retinopathy
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR).
- Trial name
- CONDOR (NCT04278417)
- Testing
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Where
- 120 sites in United States, Argentina and 14 more
- Volunteers
- 689 people
- Sponsor
- Novartis Pharmaceuticals
Nonproliferative Diabetic Retinopathy
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.
- Trial name
- NCT05383209
- Testing
- EYP-1901
- Where
- 36 sites in United States
- Volunteers
- 77 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Proliferative Diabetic Retinopathy
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
- Trial name
- NCT00170742
- Testing
- Octreotide, 30 mg i.m. LAR formulation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Novartis
Macular Edema, Diabetic
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema.
- Trial name
- NCT01994291
- Testing
- Ranibizumab, PF-04634817
- Where
- 63 sites in United States, Bulgaria and 7 more
- Volunteers
- 199 people
- Sponsor
- Pfizer
Type 1 Diabetes
DIabetic Retinopathy Candesartan Trials.
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252720)
- Testing
- candesartan
- Volunteers
- 1,850 people
- Sponsor
- AstraZeneca
Type2 Diabetes, Diabetic Retinopathy
Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy
This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.
- Trial name
- NCT05007262
- Testing
- Tangningtongluo tablets, Calcium dobesilate capsules
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
Diabetic Macular Edema (DME)
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in…
- Trial name
- NCT04857996
- Testing
- UBX1325
- Where
- 22 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Retinopathy, Diabetic Eye Problems
Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
The duration of diabetes is directly related to eye complications. Diabetic retinopathy affects 80 percent of those who have had diabetes for 20 years or more.
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT04805541
- Testing
- Color Fundus Photography, Mydriatic Agent, EyeCheckup - AI Based DR Screening
- Where
- Turkey (Türkiye)
- Volunteers
- 900 people
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Macular Edema
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).
- Trial name
- NCT04292912
- Testing
- GSK2798745
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment
This study is open to adults with diabetic macular ischemia who have received laser treatment. The main purpose of this study is to find out whether people with diabetic macular ischemia can tolerate a medicine called BI 765128.
- Trial name
- PARTRIDGE (NCT04919499)
- Testing
- BI 765128
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy, Diabetic Macular Edema
OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases
Evolucare OphtAI is a medical device offering automated, artificial intelligence powered, screening capabilities for Diabetic Retinopathy, Diabetic Macular Edema, Glaucoma, ARM and AMD, whose performances will by tested through…
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Age-Related Macular Degeneration, Age-related Maculopathy
- Trial name
- OPHTAI-EVAL (NCT05752045)
- Testing
- Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device
- Where
- 12 sites in France
- Volunteers
- 1,389 people
- Sponsor
- Evolucare Technologies
Macular Edema
Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.
- Trial name
- AQUA (NCT02581995)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 76 sites in Austria, Canada and 12 more
- Volunteers
- 560 people
- Sponsor
- Bayer
Diabetes, Diabetic Retinopathy
Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy
In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and…
- Trial name
- NCT07151001
- Testing
- No intervention
- Where
- United States
- Volunteers
- 922 people, healthy volunteers welcome
- Sponsor
- iHealthScreen Inc
Diabetic Retinopathy, Diabetes
OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection
In the United States, only 62% of the 37 million people with diabetes receive annual screening exams for diabetic retinopathy. One of the goals of the US Department of Health and Human Services Healthy People 2030 campaign is to…
- Trial name
- NCT06343350
- Testing
- OPTDR01 software application
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Optain Health
Macular Edema
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take…
- Trial name
- NCT06962839
- Testing
- BI 1815368
- Where
- 97 sites in United States, China and 7 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.
- Trial name
- NCT06321302
- Testing
- BI 764524, Aflibercept (Eylea®) - US only
- Where
- 90 sites in United States, Germany and 7 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim